Magee Thomson Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Magee Thomson Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-19,050	Closed	-$10.3M	–	111
2015 Q4	$10.3M	Buy	19,050 +2,560	+16%	+$1.39M	2.85%	19
2015 Q3	$7.67M	Buy	16,490 +2,350	+17%	+$1.26M	2.36%	22
2015 Q2	$7.21M	Sell	14,140 -26,220	-65%	-$12.8M	2.09%	29
2015 Q1	$18.2M	Sell	40,360 -980	-2%	-$415K	4.41%	4
2014 Q4	$17M	Buy	41,340 +1,630	+4%	+$641K	4.22%	5
2014 Q3	$14.3M	Buy	39,710 +1,880	+5%	+$630K	3.53%	9
2014 Q2	$10.7M	Sell	37,830 -2,980	-7%	-$883K	2.61%	21
2014 Q1	$12.3M	Buy	40,810 +305	+0.8%	+$94K	2.78%	21
2013 Q4	$11.1M	Sell	40,505 -199	-0.5%	-$57.2K	2.47%	25
2013 Q3	$12.7M	Buy	+40,704	New	+$10.7M	2.56%	26

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Magee Thomson Investment Partners's REGN Position: Q1 2016 in Review

Magee Thomson Investment Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2016, closing a stake of 19,050 shares — an estimated $10.3M sold.

Magee Thomson Investment Partners first reported a position in REGN in Q3 2013 and held it in 10 quarters. The position peaked at $18.2M in Q1 2015. 549 funds tracked by Wall St. Rank hold REGN as of Q1 2016.

Magee Thomson Investment Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Magee Thomson Investment Partners sold 19,050 Regeneron Pharmaceuticals shares in Q1 2016, an estimated $10.3M.
Magee Thomson Investment Partners first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 10 quarters.
Magee Thomson Investment Partners's Regeneron Pharmaceuticals position peaked at $18.2M in Q1 2015.
549 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2016.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2016, filed 20 Apr 2016.